The human T-lymphotropic virus type 1 (HTLV-1) retrovirus infects 10–20 million people
globally, with endemic regions in southwestern Japan, the Caribbean basin, Africa, and …

Highlights•Molecular mechanisms of HTLV-1 oncogenesis.•Innate and acquired immune
response to HTLV-1.•Clonality of HTLV-1 in vivo.•We bring together the host and viral factors …

Human T-cell lymphotropic virus type-1 (HTLV-1) is aetiologically associated with adult T-
cell leukaemia/lymphoma (ATL). HTLV-1 infection can also lead to various non-malignant …

Human T-lymphotropic virus 1 (HTLV-1) has infected human beings for thousands of years,
but knowledge about the infection and its pathogenesis is only recently emerging. The virus …

Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human
retrovirus to be discovered, more than 25 years ago. HTLV-1 infects 15 to 20 million …

Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive peripheral T-cell malignancy
that develops after long-term chronic infection with human T-cell lymphotropic virus type-1 …

Human T-cell leukaemia virus type 1 (HTLV-1) is an oncogenic retrovirus that affects as
many as 20 million people worldwide. The virus is of zoonotic origin, and it is commonly …

Adult T-cell leukemia/lymphoma (ATLL), an infrequent malignancy resultant from human T-
cell lymphotropic virus type I (HTLV-1), exhibits a spectrum of phenotypes, encompassing …

Human T cell leukemia virus type 1 (HTLV-1) was the first discovered human retrovirus and
the etiologic agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical …

Background HTLV-1 infection is a neglected disease, despite producing neurological and
lymphoproliferative severe illnesses and affect over 10 million people worldwide. Roughly …